Marian Rewers
Concepts (929)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 392 | 2026 | 3842 | 20.700 |
Why?
| | Autoimmunity | 136 | 2026 | 924 | 12.160 |
Why?
| | Islets of Langerhans | 123 | 2026 | 832 | 11.750 |
Why?
| | Autoantibodies | 189 | 2026 | 1497 | 11.280 |
Why?
| | Celiac Disease | 54 | 2026 | 308 | 7.090 |
Why?
| | Genetic Predisposition to Disease | 97 | 2026 | 2359 | 4.390 |
Why?
| | Coronary Artery Disease | 34 | 2018 | 741 | 3.250 |
Why?
| | Diabetic Angiopathies | 28 | 2017 | 254 | 3.070 |
Why?
| | Child, Preschool | 211 | 2026 | 11774 | 2.970 |
Why?
| | HLA-DQ Antigens | 38 | 2025 | 173 | 2.940 |
Why?
| | Child | 244 | 2026 | 22537 | 2.830 |
Why?
| | Calcinosis | 23 | 2015 | 233 | 2.770 |
Why?
| | HLA-DR Antigens | 28 | 2021 | 220 | 2.650 |
Why?
| | Insulin Resistance | 55 | 2018 | 1232 | 2.540 |
Why?
| | Insulin | 76 | 2026 | 2501 | 2.470 |
Why?
| | Disease Progression | 83 | 2026 | 2840 | 2.400 |
Why?
| | Infant | 170 | 2026 | 10022 | 2.390 |
Why?
| | Risk Factors | 166 | 2026 | 10699 | 2.260 |
Why?
| | Humans | 514 | 2026 | 144261 | 2.120 |
Why?
| | Diabetic Ketoacidosis | 16 | 2026 | 209 | 2.110 |
Why?
| | Transglutaminases | 30 | 2026 | 159 | 2.020 |
Why?
| | Polymorphism, Single Nucleotide | 39 | 2026 | 2143 | 2.010 |
Why?
| | Blood Glucose | 38 | 2022 | 2312 | 2.000 |
Why?
| | Genotype | 63 | 2026 | 1833 | 1.970 |
Why?
| | Autoimmune Diseases | 17 | 2026 | 463 | 1.960 |
Why?
| | Male | 349 | 2026 | 72035 | 1.900 |
Why?
| | Prospective Studies | 101 | 2026 | 7970 | 1.880 |
Why?
| | Biomarkers | 50 | 2026 | 4254 | 1.870 |
Why?
| | Insulin Antibodies | 24 | 2026 | 103 | 1.840 |
Why?
| | Female | 357 | 2026 | 77976 | 1.840 |
Why?
| | Adolescent | 149 | 2026 | 22281 | 1.840 |
Why?
| | Mass Screening | 23 | 2026 | 1332 | 1.690 |
Why?
| | Glutamate Decarboxylase | 35 | 2025 | 165 | 1.630 |
Why?
| | Hyperglycemia | 11 | 2026 | 374 | 1.590 |
Why?
| | Diabetic Nephropathies | 19 | 2020 | 314 | 1.570 |
Why?
| | Insulin-Secreting Cells | 15 | 2023 | 387 | 1.470 |
Why?
| | Coronary Disease | 15 | 2010 | 381 | 1.420 |
Why?
| | Prediabetic State | 14 | 2023 | 243 | 1.400 |
Why?
| | Diet | 31 | 2026 | 1271 | 1.390 |
Why?
| | Case-Control Studies | 60 | 2026 | 3592 | 1.380 |
Why?
| | Follow-Up Studies | 66 | 2026 | 5389 | 1.260 |
Why?
| | HLA Antigens | 24 | 2025 | 225 | 1.200 |
Why?
| | Health Care Costs | 2 | 2025 | 421 | 1.190 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 10 | 2022 | 48 | 1.180 |
Why?
| | Glutens | 11 | 2023 | 59 | 1.150 |
Why?
| | Diabetes Mellitus, Type 2 | 36 | 2025 | 2516 | 1.120 |
Why?
| | Cohort Studies | 68 | 2026 | 5935 | 1.120 |
Why?
| | Fatty Acids, Omega-3 | 8 | 2020 | 142 | 1.080 |
Why?
| | Enterovirus Infections | 6 | 2023 | 173 | 1.050 |
Why?
| | HLA-DR3 Antigen | 17 | 2025 | 76 | 1.030 |
Why?
| | Polymorphism, Genetic | 15 | 2019 | 612 | 1.020 |
Why?
| | Adult | 160 | 2026 | 40262 | 1.010 |
Why?
| | Environment | 5 | 2018 | 305 | 1.000 |
Why?
| | DNA Methylation | 8 | 2026 | 681 | 0.980 |
Why?
| | Infant, Newborn | 67 | 2026 | 6424 | 0.980 |
Why?
| | H(+)-K(+)-Exchanging ATPase | 2 | 2017 | 8 | 0.950 |
Why?
| | Erythrocyte Membrane | 5 | 2015 | 54 | 0.940 |
Why?
| | Atherosclerosis | 15 | 2018 | 404 | 0.900 |
Why?
| | HLA-DR4 Antigen | 17 | 2025 | 74 | 0.890 |
Why?
| | Longitudinal Studies | 31 | 2026 | 2926 | 0.870 |
Why?
| | Colorado | 44 | 2024 | 4562 | 0.860 |
Why?
| | Age of Onset | 20 | 2026 | 536 | 0.860 |
Why?
| | Middle Aged | 137 | 2025 | 35762 | 0.850 |
Why?
| | Diabetes Complications | 7 | 2019 | 220 | 0.820 |
Why?
| | Coronary Vessels | 8 | 2017 | 251 | 0.820 |
Why?
| | Albuminuria | 12 | 2016 | 187 | 0.820 |
Why?
| | Incidence | 36 | 2022 | 2870 | 0.820 |
Why?
| | Enterovirus | 5 | 2019 | 82 | 0.810 |
Why?
| | Seroconversion | 7 | 2026 | 49 | 0.790 |
Why?
| | Vitamin D | 8 | 2026 | 399 | 0.780 |
Why?
| | Proportional Hazards Models | 26 | 2024 | 1322 | 0.770 |
Why?
| | Vascular Calcification | 9 | 2018 | 110 | 0.760 |
Why?
| | Predictive Value of Tests | 25 | 2019 | 2111 | 0.730 |
Why?
| | Young Adult | 53 | 2026 | 13990 | 0.710 |
Why?
| | Glucose Tolerance Test | 26 | 2022 | 360 | 0.700 |
Why?
| | C-Peptide | 7 | 2025 | 186 | 0.680 |
Why?
| | Breast Feeding | 18 | 2021 | 448 | 0.670 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 12 | 2025 | 54 | 0.660 |
Why?
| | Inflammation | 10 | 2026 | 2877 | 0.660 |
Why?
| | Genetic Testing | 8 | 2019 | 478 | 0.660 |
Why?
| | Haplotypes | 15 | 2026 | 490 | 0.660 |
Why?
| | Fatty Acids | 6 | 2021 | 450 | 0.650 |
Why?
| | Calcium | 8 | 2023 | 1182 | 0.640 |
Why?
| | Zinc Transporter 8 | 8 | 2025 | 70 | 0.630 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2022 | 699 | 0.630 |
Why?
| | Antibodies, Viral | 6 | 2023 | 672 | 0.610 |
Why?
| | Autoantigens | 9 | 2025 | 429 | 0.600 |
Why?
| | GTP-Binding Proteins | 8 | 2026 | 153 | 0.600 |
Why?
| | Early Diagnosis | 7 | 2025 | 247 | 0.560 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2021 | 149 | 0.560 |
Why?
| | Prevalence | 23 | 2024 | 2815 | 0.560 |
Why?
| | Uric Acid | 6 | 2018 | 166 | 0.560 |
Why?
| | Cross-Sectional Studies | 36 | 2025 | 5813 | 0.540 |
Why?
| | Body Mass Index | 23 | 2025 | 2420 | 0.540 |
Why?
| | Germany | 12 | 2024 | 138 | 0.520 |
Why?
| | Logistic Models | 24 | 2017 | 2104 | 0.520 |
Why?
| | Infant Food | 7 | 2018 | 64 | 0.520 |
Why?
| | Smoking | 9 | 2025 | 1468 | 0.520 |
Why?
| | Adiponectin | 5 | 2016 | 243 | 0.510 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2016 | 97 | 0.510 |
Why?
| | Sensitivity and Specificity | 22 | 2026 | 1983 | 0.500 |
Why?
| | Edible Grain | 4 | 2008 | 49 | 0.500 |
Why?
| | Prognosis | 21 | 2026 | 4278 | 0.500 |
Why?
| | Finland | 16 | 2025 | 79 | 0.500 |
Why?
| | Fibrinogen | 5 | 2019 | 176 | 0.500 |
Why?
| | Glomerular Filtration Rate | 15 | 2020 | 758 | 0.490 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 289 | 0.490 |
Why?
| | Metabolomics | 5 | 2021 | 726 | 0.480 |
Why?
| | Age Factors | 38 | 2026 | 3313 | 0.480 |
Why?
| | Arteriosclerosis | 17 | 2004 | 84 | 0.480 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2013 | 427 | 0.470 |
Why?
| | Genome-Wide Association Study | 10 | 2026 | 1406 | 0.460 |
Why?
| | Hypoglycemia | 5 | 2014 | 477 | 0.460 |
Why?
| | Lipids | 5 | 2019 | 700 | 0.450 |
Why?
| | Triglycerides | 13 | 2020 | 512 | 0.450 |
Why?
| | Hypertension | 11 | 2021 | 1254 | 0.450 |
Why?
| | Milk | 7 | 2017 | 119 | 0.450 |
Why?
| | Luminescent Measurements | 4 | 2021 | 76 | 0.440 |
Why?
| | Environmental Exposure | 4 | 2025 | 587 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 7 | 2025 | 674 | 0.440 |
Why?
| | Probiotics | 3 | 2022 | 61 | 0.430 |
Why?
| | C-Reactive Protein | 5 | 2018 | 416 | 0.430 |
Why?
| | Helicobacter Infections | 1 | 2014 | 30 | 0.430 |
Why?
| | Helicobacter pylori | 1 | 2014 | 45 | 0.420 |
Why?
| | Risk | 17 | 2020 | 909 | 0.420 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 396 | 0.420 |
Why?
| | Antibodies | 5 | 2024 | 401 | 0.410 |
Why?
| | Micronutrients | 3 | 2026 | 96 | 0.410 |
Why?
| | Dietary Supplements | 7 | 2024 | 575 | 0.400 |
Why?
| | Time Factors | 21 | 2018 | 7155 | 0.400 |
Why?
| | Asymptomatic Diseases | 3 | 2023 | 97 | 0.400 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2014 | 54 | 0.400 |
Why?
| | Inflammation Mediators | 3 | 2026 | 508 | 0.400 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 31 | 0.400 |
Why?
| | Sweden | 13 | 2024 | 111 | 0.400 |
Why?
| | Immunogenetics | 1 | 2013 | 7 | 0.400 |
Why?
| | Dyslipidemias | 4 | 2015 | 171 | 0.390 |
Why?
| | Alleles | 14 | 2021 | 878 | 0.390 |
Why?
| | Glucose Clamp Technique | 8 | 2020 | 199 | 0.390 |
Why?
| | Risk Assessment | 17 | 2021 | 3637 | 0.380 |
Why?
| | Proteomics | 6 | 2025 | 1191 | 0.380 |
Why?
| | HLA-D Antigens | 5 | 2019 | 30 | 0.380 |
Why?
| | United States | 35 | 2025 | 15876 | 0.370 |
Why?
| | Bacteriophages | 2 | 2025 | 111 | 0.370 |
Why?
| | Dietary Fats | 3 | 2014 | 313 | 0.370 |
Why?
| | Child Nutritional Physiological Phenomena | 4 | 2019 | 106 | 0.370 |
Why?
| | Oxylipins | 3 | 2023 | 47 | 0.370 |
Why?
| | Fasting | 12 | 2015 | 276 | 0.370 |
Why?
| | Cost-Benefit Analysis | 4 | 2026 | 623 | 0.360 |
Why?
| | Genetic Variation | 4 | 2026 | 982 | 0.360 |
Why?
| | Epitopes | 6 | 2025 | 485 | 0.360 |
Why?
| | Vitamin D Deficiency | 2 | 2011 | 185 | 0.360 |
Why?
| | Lipoproteins | 4 | 2015 | 163 | 0.350 |
Why?
| | Apolipoproteins A | 2 | 2006 | 17 | 0.350 |
Why?
| | Ascorbic Acid | 4 | 2023 | 179 | 0.350 |
Why?
| | Addison Disease | 6 | 2012 | 38 | 0.340 |
Why?
| | Major Histocompatibility Complex | 6 | 2026 | 229 | 0.340 |
Why?
| | Liver | 3 | 2012 | 1884 | 0.340 |
Why?
| | Life Style | 5 | 2015 | 475 | 0.330 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.330 |
Why?
| | Fetal Blood | 6 | 2021 | 342 | 0.330 |
Why?
| | Sex Factors | 20 | 2020 | 2096 | 0.330 |
Why?
| | Hypolipidemic Agents | 2 | 2010 | 86 | 0.330 |
Why?
| | Dietary Proteins | 4 | 2019 | 136 | 0.330 |
Why?
| | Hypoglycemic Agents | 8 | 2020 | 1379 | 0.320 |
Why?
| | Cholesterol, HDL | 8 | 2015 | 194 | 0.320 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 729 | 0.320 |
Why?
| | Plant Proteins | 1 | 2011 | 112 | 0.320 |
Why?
| | Precision Medicine | 1 | 2014 | 456 | 0.310 |
Why?
| | Epidemics | 1 | 2011 | 98 | 0.310 |
Why?
| | Research | 2 | 2013 | 428 | 0.310 |
Why?
| | Eating | 5 | 2023 | 389 | 0.310 |
Why?
| | Surveys and Questionnaires | 17 | 2024 | 6021 | 0.310 |
Why?
| | Patient Education as Topic | 2 | 2005 | 777 | 0.310 |
Why?
| | Blood Proteins | 3 | 2017 | 249 | 0.300 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.300 |
Why?
| | HLA-DQ beta-Chains | 12 | 2019 | 57 | 0.300 |
Why?
| | CTLA-4 Antigen | 5 | 2017 | 104 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2025 | 1128 | 0.300 |
Why?
| | Cesarean Section | 2 | 2024 | 224 | 0.300 |
Why?
| | Cystatin C | 6 | 2014 | 65 | 0.300 |
Why?
| | Obesity | 12 | 2015 | 3057 | 0.300 |
Why?
| | Family Health | 8 | 2017 | 191 | 0.290 |
Why?
| | Cytokines | 6 | 2026 | 2061 | 0.290 |
Why?
| | Multivariate Analysis | 10 | 2016 | 1533 | 0.290 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1050 | 0.290 |
Why?
| | Sex Distribution | 6 | 2011 | 380 | 0.290 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 37 | 0.290 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 771 | 0.280 |
Why?
| | Rotavirus | 2 | 2016 | 20 | 0.280 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.280 |
Why?
| | Antigens, CD | 2 | 2009 | 555 | 0.280 |
Why?
| | Feces | 7 | 2025 | 513 | 0.270 |
Why?
| | Diabetes Mellitus | 8 | 2009 | 1092 | 0.270 |
Why?
| | Europe | 11 | 2021 | 412 | 0.270 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.270 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.270 |
Why?
| | Adiposity | 7 | 2020 | 541 | 0.260 |
Why?
| | Epigenesis, Genetic | 4 | 2026 | 684 | 0.260 |
Why?
| | Reference Values | 10 | 2012 | 797 | 0.260 |
Why?
| | Pregnancy | 18 | 2025 | 7180 | 0.260 |
Why?
| | Seroepidemiologic Studies | 4 | 2023 | 172 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 12 | 2018 | 2730 | 0.260 |
Why?
| | Carotenoids | 2 | 2026 | 48 | 0.260 |
Why?
| | Gene-Environment Interaction | 5 | 2024 | 180 | 0.260 |
Why?
| | Diet, Gluten-Free | 3 | 2024 | 56 | 0.260 |
Why?
| | Glycopeptides | 2 | 2018 | 44 | 0.250 |
Why?
| | Proteome | 2 | 2025 | 514 | 0.250 |
Why?
| | Iron | 3 | 2023 | 359 | 0.250 |
Why?
| | Survival Analysis | 4 | 2021 | 1382 | 0.250 |
Why?
| | Adipose Tissue | 4 | 2018 | 651 | 0.250 |
Why?
| | HLA-DRB1 Chains | 8 | 2019 | 109 | 0.250 |
Why?
| | Patient Compliance | 3 | 2023 | 585 | 0.250 |
Why?
| | Metabolome | 2 | 2020 | 384 | 0.250 |
Why?
| | Rotavirus Infections | 1 | 2006 | 35 | 0.250 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.250 |
Why?
| | RNA, Viral | 3 | 2019 | 687 | 0.240 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2011 | 202 | 0.240 |
Why?
| | Exercise | 4 | 2023 | 2193 | 0.240 |
Why?
| | Tocopherols | 1 | 2026 | 30 | 0.240 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.240 |
Why?
| | Remission Induction | 2 | 2004 | 306 | 0.240 |
Why?
| | Vitamin A | 1 | 2026 | 59 | 0.240 |
Why?
| | HLA-DR alpha-Chains | 1 | 2026 | 5 | 0.240 |
Why?
| | Complement C4a | 1 | 2026 | 9 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 221 | 0.240 |
Why?
| | Overweight | 3 | 2021 | 606 | 0.240 |
Why?
| | Regression Analysis | 15 | 2014 | 998 | 0.240 |
Why?
| | Infant Formula | 3 | 2019 | 71 | 0.240 |
Why?
| | Contraception | 1 | 2008 | 169 | 0.230 |
Why?
| | Cardiovascular Diseases | 8 | 2018 | 2134 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 7 | 2006 | 167 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.230 |
Why?
| | Carotid Arteries | 5 | 1998 | 199 | 0.230 |
Why?
| | Chromosome Mapping | 4 | 2025 | 509 | 0.230 |
Why?
| | Hypersensitivity, Immediate | 1 | 2025 | 40 | 0.230 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 374 | 0.230 |
Why?
| | Gene Frequency | 10 | 2020 | 481 | 0.230 |
Why?
| | Maternal Age | 3 | 2004 | 126 | 0.230 |
Why?
| | Aged | 45 | 2021 | 25850 | 0.230 |
Why?
| | Diet Records | 4 | 2019 | 85 | 0.220 |
Why?
| | Proinsulin | 3 | 2014 | 51 | 0.220 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2025 | 15 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2011 | 364 | 0.220 |
Why?
| | Glucose Intolerance | 7 | 2013 | 142 | 0.220 |
Why?
| | Tobacco Smoke Pollution | 4 | 2019 | 233 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 6 | 2017 | 84 | 0.220 |
Why?
| | Apolipoproteins | 3 | 2014 | 37 | 0.220 |
Why?
| | Introns | 1 | 2026 | 254 | 0.220 |
Why?
| | Abdominal Wall | 1 | 2004 | 27 | 0.220 |
Why?
| | Mass Spectrometry | 4 | 2025 | 744 | 0.220 |
Why?
| | Linear Models | 7 | 2016 | 850 | 0.220 |
Why?
| | Docosahexaenoic Acids | 3 | 2021 | 83 | 0.220 |
Why?
| | Immunotherapy | 1 | 2009 | 652 | 0.210 |
Why?
| | Health Surveys | 3 | 2018 | 510 | 0.210 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 509 | 0.210 |
Why?
| | Hyperlipidemias | 1 | 2005 | 121 | 0.210 |
Why?
| | Immunoglobulin A | 6 | 2024 | 214 | 0.210 |
Why?
| | Bone Density | 2 | 2020 | 482 | 0.210 |
Why?
| | Delivery, Obstetric | 2 | 2004 | 160 | 0.210 |
Why?
| | Fever | 1 | 2025 | 311 | 0.200 |
Why?
| | Vitamin B Complex | 1 | 2024 | 40 | 0.200 |
Why?
| | Animals | 26 | 2022 | 38030 | 0.200 |
Why?
| | Coronary Angiography | 2 | 2014 | 322 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Seasons | 5 | 2024 | 556 | 0.200 |
Why?
| | Peptide Library | 1 | 2024 | 95 | 0.200 |
Why?
| | Alanine Transaminase | 2 | 2015 | 151 | 0.200 |
Why?
| | Haptoglobins | 3 | 2013 | 66 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 850 | 0.200 |
Why?
| | Birth Weight | 4 | 2016 | 522 | 0.200 |
Why?
| | Iron Overload | 1 | 2023 | 19 | 0.190 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 381 | 0.190 |
Why?
| | Child Development | 2 | 2020 | 484 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 170 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 1792 | 0.190 |
Why?
| | Virus Diseases | 4 | 2021 | 216 | 0.190 |
Why?
| | ROC Curve | 4 | 2019 | 612 | 0.190 |
Why?
| | Ketone Bodies | 2 | 2014 | 15 | 0.190 |
Why?
| | Alcohol Drinking | 1 | 2009 | 812 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 964 | 0.180 |
Why?
| | Influenza, Human | 2 | 2022 | 615 | 0.180 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 218 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 434 | 0.180 |
Why?
| | Complement System Proteins | 1 | 2025 | 316 | 0.180 |
Why?
| | Diabetic Retinopathy | 4 | 2016 | 207 | 0.180 |
Why?
| | Pediatrics | 4 | 2020 | 1112 | 0.180 |
Why?
| | Mothers | 4 | 2021 | 774 | 0.180 |
Why?
| | Lipid Metabolism | 2 | 2019 | 525 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2021 | 181 | 0.180 |
Why?
| | Peptides | 3 | 2024 | 995 | 0.180 |
Why?
| | Blood Pressure | 9 | 2014 | 1759 | 0.180 |
Why?
| | T-Lymphocytes | 3 | 2025 | 1982 | 0.180 |
Why?
| | Age Distribution | 5 | 2011 | 397 | 0.180 |
Why?
| | Parents | 6 | 2023 | 1401 | 0.170 |
Why?
| | Odds Ratio | 6 | 2015 | 1072 | 0.170 |
Why?
| | Lipase | 1 | 2002 | 74 | 0.170 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2021 | 13 | 0.170 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2021 | 49 | 0.170 |
Why?
| | Monitoring, Ambulatory | 2 | 2014 | 88 | 0.170 |
Why?
| | Glycerol | 2 | 2012 | 90 | 0.170 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 55 | 0.170 |
Why?
| | Growth | 2 | 2016 | 49 | 0.170 |
Why?
| | Reproducibility of Results | 9 | 2021 | 3403 | 0.170 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1255 | 0.170 |
Why?
| | Body Height | 3 | 2014 | 202 | 0.170 |
Why?
| | White Matter | 1 | 2023 | 151 | 0.170 |
Why?
| | Polysaccharides | 2 | 2022 | 87 | 0.170 |
Why?
| | Gastroenteritis | 2 | 2016 | 63 | 0.170 |
Why?
| | Gestational Age | 3 | 2020 | 975 | 0.170 |
Why?
| | F2-Isoprostanes | 2 | 2015 | 20 | 0.160 |
Why?
| | Bacteria | 2 | 2025 | 889 | 0.160 |
Why?
| | Luminescence | 3 | 2016 | 39 | 0.160 |
Why?
| | Vitamins | 2 | 2020 | 178 | 0.160 |
Why?
| | HLA-B8 Antigen | 4 | 2012 | 11 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2026 | 876 | 0.160 |
Why?
| | Ketosis | 1 | 2020 | 12 | 0.160 |
Why?
| | Influenza Vaccines | 2 | 2017 | 529 | 0.160 |
Why?
| | Neutrophils | 1 | 2026 | 1134 | 0.160 |
Why?
| | Genomics | 2 | 2021 | 833 | 0.160 |
Why?
| | Disease Susceptibility | 6 | 2020 | 346 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2015 | 150 | 0.160 |
Why?
| | Dietary Sucrose | 1 | 2020 | 49 | 0.160 |
Why?
| | Biopsy | 5 | 2017 | 1075 | 0.160 |
Why?
| | Neonatal Screening | 4 | 2020 | 178 | 0.160 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.160 |
Why?
| | Sugars | 1 | 2020 | 41 | 0.160 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 21 | 0.160 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 117 | 0.150 |
Why?
| | Energy Intake | 5 | 2023 | 499 | 0.150 |
Why?
| | Life Change Events | 1 | 2021 | 144 | 0.150 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 610 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 84 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 211 | 0.150 |
Why?
| | Developing Countries | 2 | 1993 | 314 | 0.150 |
Why?
| | Metabolic Clearance Rate | 3 | 2014 | 114 | 0.150 |
Why?
| | Kidney | 2 | 2018 | 1495 | 0.150 |
Why?
| | Oxidative Stress | 3 | 2017 | 1339 | 0.150 |
Why?
| | Epidemiologic Methods | 4 | 2014 | 89 | 0.150 |
Why?
| | Apolipoproteins B | 2 | 2015 | 45 | 0.150 |
Why?
| | Cation Transport Proteins | 3 | 2011 | 118 | 0.150 |
Why?
| | Measles | 1 | 2019 | 46 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2003 | 422 | 0.150 |
Why?
| | Iodide Peroxidase | 5 | 2025 | 34 | 0.150 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 61 | 0.150 |
Why?
| | Glycosuria | 2 | 2009 | 10 | 0.150 |
Why?
| | Fatty Acids, Omega-6 | 4 | 2020 | 48 | 0.150 |
Why?
| | Butyrates | 1 | 2019 | 67 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2019 | 148 | 0.140 |
Why?
| | Cotinine | 1 | 2019 | 79 | 0.140 |
Why?
| | Genetic Markers | 4 | 2013 | 331 | 0.140 |
Why?
| | Genes, MHC Class II | 3 | 2012 | 76 | 0.140 |
Why?
| | Uromodulin | 1 | 2018 | 22 | 0.140 |
Why?
| | Cholesterol | 5 | 2014 | 399 | 0.140 |
Why?
| | Mexican Americans | 3 | 2014 | 114 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 252 | 0.140 |
Why?
| | Health Expenditures | 1 | 2020 | 194 | 0.140 |
Why?
| | HLA-DP beta-Chains | 3 | 2015 | 87 | 0.140 |
Why?
| | Self Report | 3 | 2020 | 863 | 0.140 |
Why?
| | Models, Biological | 5 | 2019 | 1820 | 0.140 |
Why?
| | Squalene | 1 | 2017 | 8 | 0.130 |
Why?
| | HLA-DR2 Antigen | 2 | 2012 | 8 | 0.130 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.130 |
Why?
| | Amino Acid Sequence | 6 | 2024 | 2154 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 47 | 0.130 |
Why?
| | Phenotype | 8 | 2024 | 3157 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 374 | 0.130 |
Why?
| | Antipyretics | 1 | 2017 | 5 | 0.130 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 174 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 319 | 0.130 |
Why?
| | Feeding Behavior | 3 | 2013 | 681 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2017 | 1782 | 0.130 |
Why?
| | Radioimmunoassay | 6 | 2016 | 165 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2019 | 366 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 54 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 379 | 0.130 |
Why?
| | Body Composition | 3 | 2020 | 704 | 0.130 |
Why?
| | Rheumatoid Factor | 3 | 2007 | 175 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 535 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 236 | 0.130 |
Why?
| | Genetic Loci | 3 | 2015 | 261 | 0.130 |
Why?
| | Kidney Diseases | 2 | 2012 | 425 | 0.130 |
Why?
| | Rural Health | 2 | 2002 | 87 | 0.130 |
Why?
| | Poland | 4 | 2010 | 34 | 0.120 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 59 | 0.120 |
Why?
| | Milk Proteins | 1 | 1996 | 35 | 0.120 |
Why?
| | Toxins, Biological | 1 | 2016 | 12 | 0.120 |
Why?
| | Homozygote | 5 | 2014 | 199 | 0.120 |
Why?
| | Arachidonic Acid | 2 | 2021 | 101 | 0.120 |
Why?
| | Body Weight | 3 | 2016 | 976 | 0.120 |
Why?
| | Models, Theoretical | 2 | 2017 | 582 | 0.120 |
Why?
| | Immunoglobulin G | 4 | 2021 | 893 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1021 | 0.120 |
Why?
| | Patient Care Planning | 2 | 2015 | 169 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2017 | 127 | 0.120 |
Why?
| | Hygiene | 1 | 2016 | 29 | 0.120 |
Why?
| | HLA-A1 Antigen | 2 | 2006 | 3 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 7 | 2006 | 44 | 0.120 |
Why?
| | HLA-DP Antigens | 2 | 2007 | 32 | 0.120 |
Why?
| | Diet Surveys | 4 | 2021 | 91 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 79 | 0.120 |
Why?
| | Polymerase Chain Reaction | 5 | 2011 | 1054 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 123 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Feeding Methods | 1 | 2015 | 5 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1559 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 758 | 0.110 |
Why?
| | Histocompatibility Testing | 6 | 2017 | 121 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 549 | 0.110 |
Why?
| | Medical Records | 2 | 2007 | 186 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 275 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2018 | 653 | 0.110 |
Why?
| | Complement C3 | 1 | 2016 | 191 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2021 | 1147 | 0.110 |
Why?
| | Genetic Association Studies | 4 | 2020 | 372 | 0.110 |
Why?
| | Carbohydrates | 1 | 2015 | 66 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2015 | 58 | 0.110 |
Why?
| | Child Day Care Centers | 1 | 2015 | 44 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 995 | 0.110 |
Why?
| | Erythrocytes | 1 | 2021 | 757 | 0.110 |
Why?
| | Up-Regulation | 2 | 2016 | 851 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 30 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | Fructosamine | 1 | 2014 | 11 | 0.110 |
Why?
| | Gram-Positive Bacteria | 1 | 2014 | 47 | 0.110 |
Why?
| | Video Recording | 2 | 2015 | 211 | 0.110 |
Why?
| | Health Records, Personal | 1 | 2014 | 26 | 0.110 |
Why?
| | Dairy Products | 1 | 2014 | 31 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2015 | 273 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.110 |
Why?
| | Carotid Artery Diseases | 3 | 2000 | 68 | 0.110 |
Why?
| | Societies, Scientific | 1 | 2014 | 49 | 0.110 |
Why?
| | Acetaminophen | 1 | 2017 | 264 | 0.110 |
Why?
| | Gram-Negative Bacteria | 1 | 2014 | 81 | 0.110 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2929 | 0.100 |
Why?
| | Bias | 1 | 2015 | 201 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 338 | 0.100 |
Why?
| | Renal Insufficiency | 1 | 2016 | 168 | 0.100 |
Why?
| | Eicosapentaenoic Acid | 1 | 2013 | 36 | 0.100 |
Why?
| | Cholesterol, Dietary | 1 | 2013 | 15 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1119 | 0.100 |
Why?
| | Siblings | 3 | 2018 | 195 | 0.100 |
Why?
| | Gene Expression | 3 | 2021 | 1487 | 0.100 |
Why?
| | Eggs | 1 | 2013 | 25 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 179 | 0.100 |
Why?
| | Creatinine | 4 | 2018 | 505 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 321 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2023 | 668 | 0.100 |
Why?
| | Research Support as Topic | 1 | 2013 | 79 | 0.100 |
Why?
| | Heart Rate | 3 | 2010 | 849 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 163 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.090 |
Why?
| | Mice | 11 | 2022 | 18329 | 0.090 |
Why?
| | Biological Specimen Banks | 1 | 2013 | 101 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2012 | 25 | 0.090 |
Why?
| | Organizational Innovation | 1 | 2013 | 120 | 0.090 |
Why?
| | Anesthesiology | 1 | 2015 | 175 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2022 | 846 | 0.090 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | History, 21st Century | 1 | 2013 | 219 | 0.090 |
Why?
| | Stomach | 1 | 2012 | 109 | 0.090 |
Why?
| | Sex Characteristics | 7 | 2015 | 789 | 0.090 |
Why?
| | CpG Islands | 2 | 2023 | 165 | 0.090 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 66 | 0.090 |
Why?
| | Interleukin-4 | 2 | 2005 | 206 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1867 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 382 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 324 | 0.090 |
Why?
| | Specimen Handling | 1 | 2013 | 185 | 0.090 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 102 | 0.090 |
Why?
| | Intestine, Small | 2 | 2005 | 166 | 0.090 |
Why?
| | Nuclear Family | 2 | 2009 | 52 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2010 | 113 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 31 | 0.090 |
Why?
| | Intestines | 1 | 2014 | 358 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 905 | 0.090 |
Why?
| | Pedigree | 4 | 2017 | 513 | 0.090 |
Why?
| | Gliadin | 2 | 2009 | 13 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1264 | 0.090 |
Why?
| | Patient Selection | 3 | 2011 | 719 | 0.090 |
Why?
| | Primary Prevention | 1 | 2013 | 219 | 0.090 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 194 | 0.080 |
Why?
| | HLA-B Antigens | 1 | 2011 | 56 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2012 | 437 | 0.080 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 24 | 0.080 |
Why?
| | Vaccines | 1 | 2016 | 389 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2011 | 157 | 0.080 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 15 | 0.080 |
Why?
| | Thyroglobulin | 3 | 2025 | 29 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2026 | 0.080 |
Why?
| | Viruses | 1 | 2013 | 165 | 0.080 |
Why?
| | Vascular Diseases | 2 | 2013 | 250 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Food, Fortified | 1 | 2010 | 44 | 0.080 |
Why?
| | Weight Gain | 2 | 2011 | 556 | 0.080 |
Why?
| | Linkage Disequilibrium | 4 | 2015 | 246 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 216 | 0.080 |
Why?
| | Milk, Human | 3 | 2018 | 172 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2012 | 395 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2013 | 454 | 0.080 |
Why?
| | Nutrition Assessment | 2 | 2015 | 92 | 0.080 |
Why?
| | Lymphocyte Activation | 1 | 2014 | 1126 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2010 | 158 | 0.080 |
Why?
| | Microbiota | 2 | 2014 | 781 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 573 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Myocardial Infarction | 2 | 1994 | 1208 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 141 | 0.080 |
Why?
| | Socioeconomic Factors | 5 | 2017 | 1312 | 0.080 |
Why?
| | Family | 5 | 2018 | 679 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2002 | 1165 | 0.080 |
Why?
| | RNA | 1 | 2016 | 939 | 0.070 |
Why?
| | Transcription Factors | 1 | 2017 | 1739 | 0.070 |
Why?
| | Quality Control | 3 | 2013 | 163 | 0.070 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 37 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 352 | 0.070 |
Why?
| | Pancreas | 2 | 2023 | 341 | 0.070 |
Why?
| | Bifidobacterium | 2 | 2018 | 21 | 0.070 |
Why?
| | Homeostasis | 2 | 2010 | 640 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2011 | 824 | 0.070 |
Why?
| | Antigens, Viral | 2 | 2021 | 182 | 0.070 |
Why?
| | Algorithms | 3 | 2026 | 1834 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 102 | 0.070 |
Why?
| | Glycemic Index | 1 | 2008 | 26 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 299 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 508 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2016 | 629 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 780 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 109 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 90 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 377 | 0.070 |
Why?
| | Telomere | 3 | 2022 | 287 | 0.070 |
Why?
| | Disease Outbreaks | 2 | 1991 | 422 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 294 | 0.060 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.060 |
Why?
| | Lipoproteins, LDL | 2 | 2008 | 114 | 0.060 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.060 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.060 |
Why?
| | Clinical Competence | 1 | 2015 | 1241 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 96 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1906 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 576 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2009 | 242 | 0.060 |
Why?
| | Drug Utilization | 2 | 2017 | 166 | 0.060 |
Why?
| | Datasets as Topic | 2 | 2018 | 122 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2014 | 624 | 0.060 |
Why?
| | Physicians | 1 | 2015 | 938 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 157 | 0.060 |
Why?
| | Wheat Hypersensitivity | 1 | 2006 | 4 | 0.060 |
Why?
| | Insulin Infusion Systems | 2 | 2017 | 477 | 0.060 |
Why?
| | Population Surveillance | 3 | 2020 | 483 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 30 | 0.060 |
Why?
| | Antibody Specificity | 4 | 2011 | 181 | 0.060 |
Why?
| | Apolipoprotein C-III | 1 | 2006 | 11 | 0.060 |
Why?
| | Epitope Mapping | 2 | 2024 | 61 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 561 | 0.060 |
Why?
| | Birth Order | 2 | 2004 | 13 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 15 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 442 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2005 | 43 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 26 | 0.060 |
Why?
| | Carrier State | 1 | 2006 | 79 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Chronic Disease | 4 | 2017 | 1812 | 0.060 |
Why?
| | Metagenomics | 2 | 2019 | 181 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 427 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2005 | 25 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2012 | 454 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 77 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2026 | 96 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 304 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2005 | 44 | 0.060 |
Why?
| | Protective Factors | 2 | 2015 | 99 | 0.060 |
Why?
| | Capsid Proteins | 1 | 2005 | 95 | 0.060 |
Why?
| | Fathers | 1 | 2005 | 51 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 144 | 0.050 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.050 |
Why?
| | Norway | 2 | 2019 | 45 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 111 | 0.050 |
Why?
| | Research Design | 3 | 2019 | 1129 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 56 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 558 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4556 | 0.050 |
Why?
| | Nutritional Status | 1 | 2007 | 354 | 0.050 |
Why?
| | Survivors | 1 | 2008 | 516 | 0.050 |
Why?
| | Cattle | 3 | 2017 | 999 | 0.050 |
Why?
| | Anthropometry | 1 | 2004 | 199 | 0.050 |
Why?
| | Pennsylvania | 2 | 2018 | 136 | 0.050 |
Why?
| | Waist Circumference | 2 | 2015 | 138 | 0.050 |
Why?
| | Postmenopause | 3 | 2020 | 391 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 1044 | 0.050 |
Why?
| | Metagenome | 1 | 2025 | 149 | 0.050 |
Why?
| | Insulin, Isophane | 1 | 2003 | 22 | 0.050 |
Why?
| | DNA | 2 | 2011 | 1460 | 0.050 |
Why?
| | Cross-Cultural Comparison | 2 | 2015 | 83 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 333 | 0.050 |
Why?
| | Registries | 7 | 2019 | 2382 | 0.050 |
Why?
| | International Cooperation | 3 | 2016 | 197 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 331 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 82 | 0.050 |
Why?
| | Iron, Dietary | 1 | 2023 | 23 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 88 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2005 | 275 | 0.050 |
Why?
| | Computer Simulation | 2 | 2026 | 1025 | 0.050 |
Why?
| | Creatine | 1 | 2023 | 63 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 7 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 709 | 0.050 |
Why?
| | Markov Chains | 2 | 2020 | 126 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 129 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 354 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2019 | 16 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 462 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3119 | 0.050 |
Why?
| | Electrocardiography | 2 | 2010 | 660 | 0.050 |
Why?
| | Candida | 1 | 2022 | 44 | 0.050 |
Why?
| | Choline | 1 | 2023 | 136 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 477 | 0.050 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 11 | 0.050 |
Why?
| | Insulins | 1 | 2022 | 38 | 0.040 |
Why?
| | Prenatal Care | 1 | 2004 | 306 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 523 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 73 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 402 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 20 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | China | 1 | 2021 | 269 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 53 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 103 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Perception | 1 | 2023 | 377 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2025 | 17009 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 115 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 161 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Isotopes | 1 | 2020 | 34 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 778 | 0.040 |
Why?
| | Dehydroascorbic Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 154 | 0.040 |
Why?
| | Antibody Diversity | 1 | 2019 | 16 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 13 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2020 | 39 | 0.040 |
Why?
| | Models, Statistical | 3 | 2015 | 677 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2006 | 704 | 0.040 |
Why?
| | Glucose Transporter Type 2 | 1 | 2019 | 16 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 168 | 0.040 |
Why?
| | Growth Charts | 1 | 2020 | 20 | 0.040 |
Why?
| | Viral Proteins | 2 | 2006 | 355 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 130 | 0.040 |
Why?
| | Haemophilus influenzae type b | 1 | 1999 | 12 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 27 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 62 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 60 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 76 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1999 | 29 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 592 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2019 | 47 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 208 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1999 | 27 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 284 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 120 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 182 | 0.040 |
Why?
| | Proline | 1 | 2020 | 83 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2019 | 27 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 1999 | 43 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 103 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 131 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 162 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 315 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 191 | 0.040 |
Why?
| | Texas | 2 | 2014 | 278 | 0.040 |
Why?
| | Depression | 1 | 2009 | 1533 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 1999 | 94 | 0.040 |
Why?
| | Alanine | 1 | 2020 | 171 | 0.040 |
Why?
| | Proteobacteria | 1 | 2018 | 16 | 0.040 |
Why?
| | Maternal Behavior | 1 | 1999 | 84 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 593 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 433 | 0.040 |
Why?
| | Adenoviridae | 1 | 2019 | 199 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 585 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 47 | 0.040 |
Why?
| | Pets | 1 | 2018 | 26 | 0.040 |
Why?
| | Down-Regulation | 1 | 2021 | 627 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 343 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 318 | 0.040 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2018 | 79 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Fatty Acids, Volatile | 1 | 2018 | 60 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2020 | 192 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2000 | 247 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 41 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 431 | 0.030 |
Why?
| | Postpartum Period | 1 | 2021 | 361 | 0.030 |
Why?
| | Employment | 1 | 2020 | 185 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 167 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 252 | 0.030 |
Why?
| | Apolipoprotein A-I | 1 | 1997 | 30 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2917 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 135 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 46 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 143 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2017 | 36 | 0.030 |
Why?
| | Bicarbonates | 1 | 2017 | 45 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 366 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 455 | 0.030 |
Why?
| | Canada | 1 | 2018 | 428 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 121 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2011 | 183 | 0.030 |
Why?
| | Galactosamine | 1 | 2016 | 3 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 48 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 67 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2015 | 1087 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 519 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 173 | 0.030 |
Why?
| | Acetylglucosamine | 1 | 2016 | 13 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 327 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 363 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 336 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 37 | 0.030 |
Why?
| | Africa | 2 | 1996 | 114 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 643 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2017 | 83 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 512 | 0.030 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 14 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1104 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 157 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 313 | 0.030 |
Why?
| | Genetic Background | 1 | 2015 | 16 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 312 | 0.030 |
Why?
| | Anemia, Sickle Cell | 1 | 2000 | 309 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 80 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1253 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 496 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 768 | 0.030 |
Why?
| | Analysis of Variance | 3 | 2010 | 1304 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 83 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 511 | 0.030 |
Why?
| | Genes | 1 | 1995 | 226 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 37 | 0.030 |
Why?
| | Florida | 1 | 2015 | 116 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 439 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 315 | 0.030 |
Why?
| | Quality of Life | 2 | 2024 | 3166 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 744 | 0.030 |
Why?
| | Washington | 1 | 2015 | 146 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 242 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 674 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 329 | 0.030 |
Why?
| | Airway Management | 1 | 2015 | 79 | 0.030 |
Why?
| | Insulin, Long-Acting | 2 | 2005 | 65 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 142 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 396 | 0.030 |
Why?
| | Tunica Intima | 3 | 2000 | 78 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 143 | 0.030 |
Why?
| | Insulin Glargine | 2 | 2005 | 87 | 0.030 |
Why?
| | Achievement | 1 | 2014 | 57 | 0.030 |
Why?
| | Epidemiologic Factors | 1 | 2013 | 10 | 0.030 |
Why?
| | Hospitalization | 1 | 2004 | 2424 | 0.030 |
Why?
| | Family Characteristics | 1 | 2015 | 196 | 0.030 |
Why?
| | Asthma | 1 | 2025 | 1767 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 50 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 60 | 0.020 |
Why?
| | Base Sequence | 2 | 2011 | 2187 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2012 | 6 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 309 | 0.020 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2012 | 11 | 0.020 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 8 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 118 | 0.020 |
Why?
| | Niacinamide | 1 | 1993 | 86 | 0.020 |
Why?
| | Nurses | 1 | 2015 | 178 | 0.020 |
Why?
| | S100 Proteins | 1 | 2012 | 36 | 0.020 |
Why?
| | California | 2 | 2004 | 469 | 0.020 |
Why?
| | Vaccines, Inactivated | 1 | 2012 | 70 | 0.020 |
Why?
| | Biometry | 1 | 1993 | 68 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1646 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 320 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 152 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 151 | 0.020 |
Why?
| | Genome | 1 | 2014 | 306 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2012 | 78 | 0.020 |
Why?
| | Aging | 3 | 2000 | 1964 | 0.020 |
Why?
| | Nitrates | 1 | 1992 | 100 | 0.020 |
Why?
| | Water Supply | 1 | 1992 | 88 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2011 | 14 | 0.020 |
Why?
| | Observation | 1 | 2011 | 54 | 0.020 |
Why?
| | Potassium Channels | 1 | 2012 | 145 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2011 | 6 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1998 | 917 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2012 | 162 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 1015 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 33 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 50 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2014 | 376 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1487 | 0.020 |
Why?
| | Insulinoma | 1 | 2011 | 27 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 136 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 330 | 0.020 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.020 |
Why?
| | Causality | 1 | 1991 | 126 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 886 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2007 | 698 | 0.020 |
Why?
| | Leptin | 1 | 2012 | 244 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2015 | 586 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2930 | 0.020 |
Why?
| | Endothelium, Vascular | 2 | 2008 | 963 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 13 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 19 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 29 | 0.020 |
Why?
| | Fetal Weight | 1 | 2009 | 54 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 30 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 250 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 151 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 405 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 100 | 0.020 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 4 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8243 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 527 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 28 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2009 | 103 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1422 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 842 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 43 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 19 | 0.020 |
Why?
| | Tunica Media | 2 | 2000 | 36 | 0.020 |
Why?
| | Protein Precursors | 1 | 2009 | 136 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Survival Rate | 2 | 2006 | 2088 | 0.020 |
Why?
| | Telecommunications | 1 | 1988 | 19 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 197 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2008 | 32 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 981 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 36 | 0.020 |
Why?
| | Pacific Islands | 1 | 1988 | 5 | 0.020 |
Why?
| | Solanum tuberosum | 1 | 2008 | 8 | 0.020 |
Why?
| | Probability | 1 | 1989 | 308 | 0.020 |
Why?
| | Americas | 1 | 1988 | 26 | 0.020 |
Why?
| | Outpatients | 1 | 1992 | 439 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 112 | 0.020 |
Why?
| | Asia | 1 | 1988 | 70 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 97 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 2009 | 120 | 0.020 |
Why?
| | Survival | 1 | 2007 | 38 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 170 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1715 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 187 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 46 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 59 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2006 | 73 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2006 | 56 | 0.020 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2006 | 63 | 0.020 |
Why?
| | Serotyping | 1 | 2005 | 32 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1519 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 388 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 366 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2829 | 0.010 |
Why?
| | Species Specificity | 1 | 2006 | 574 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.010 |
Why?
| | Cause of Death | 2 | 2002 | 464 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2005 | 139 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 371 | 0.010 |
Why?
| | Puerto Rico | 1 | 2004 | 58 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 649 | 0.010 |
Why?
| | Ultrasonography | 2 | 2000 | 768 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 178 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2004 | 11643 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 121 | 0.010 |
Why?
| | Genome, Viral | 1 | 2005 | 218 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2003 | 93 | 0.010 |
Why?
| | Regeneration | 1 | 2005 | 196 | 0.010 |
Why?
| | Insulin Lispro | 1 | 2003 | 42 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 4085 | 0.010 |
Why?
| | DNA, Viral | 1 | 2005 | 358 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 311 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2182 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2005 | 267 | 0.010 |
Why?
| | Health | 1 | 2003 | 81 | 0.010 |
Why?
| | Duodenum | 1 | 2003 | 77 | 0.010 |
Why?
| | Income | 1 | 2003 | 199 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 52 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 222 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4146 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 85 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 44 | 0.010 |
Why?
| | Carotid Artery, Common | 1 | 2000 | 31 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 276 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1985 | 513 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 1999 | 5 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1028 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1999 | 81 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1999 | 109 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5221 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 1999 | 134 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1998 | 164 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 274 | 0.010 |
Why?
| | Demography | 1 | 1998 | 284 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1168 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2603 | 0.010 |
Why?
| | Quantitative Trait, Heritable | 1 | 1997 | 117 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 1998 | 353 | 0.010 |
Why?
| | Bacterial Infections | 1 | 1998 | 246 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 415 | 0.010 |
Why?
| | Mexico | 1 | 1996 | 233 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 2525 | 0.010 |
Why?
| | Mental Disorders | 1 | 2002 | 1138 | 0.010 |
Why?
| | Baltic States | 1 | 1992 | 1 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1998 | 935 | 0.010 |
Why?
| | Rats | 1 | 2000 | 5592 | 0.010 |
Why?
| | Geography | 1 | 1992 | 203 | 0.010 |
Why?
| | Software | 1 | 1997 | 690 | 0.010 |
Why?
| | Cohort Effect | 1 | 1990 | 4 | 0.000 |
Why?
| | Periodicity | 1 | 1990 | 58 | 0.000 |
Why?
| | Space-Time Clustering | 1 | 1989 | 3 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1989 | 21 | 0.000 |
Why?
| | Coxsackievirus Infections | 1 | 1987 | 14 | 0.000 |
Why?
| | Rubella | 1 | 1987 | 22 | 0.000 |
Why?
| | Mortality | 1 | 1989 | 371 | 0.000 |
Why?
| | Neoplasms | 1 | 1989 | 2870 | 0.000 |
Why?
|
|
Rewers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|